BNAI

Key Points - Tyler mentioned the Q2 10-Q filing delay was due to strengthening the company's foundation by reducing ongoing expenses, reengaging with an accounting firm, and highlighting the Korean Innovation Lab with over 30 employees driving product innovation. - Global partnership with Swiss Life was a milestone, entry into Mexico, pharmacy sector launch provided market feedback, automotive opportunities, focus on trusted data for AI. - Walid noted Q2 results showed stabilization of operations and strengthened financial position, expenses reduced by over 55%, shifting focus to driving revenue growth.

Forward-Looking - Scheduled next earnings call on November 4, 2025, and Annual Shareholder Meeting on November 26, 2025. - Focus on 3 core priorities: execution and discipline, commercial acceleration, and product leadership to drive growth with purpose.

Revenue in Q2 2025 was $5,000 compared to $0 in Q2 2024. Operating expenses decreased by 55.6% to $2.8 million from $6.3 million in Q2 2024. Other income was $3.7 million, primarily from a gain on debt extinguishment. Net income was $900,000 in Q2 2025 compared to a net loss of $3 million in Q2 2024. Stockholders' equity increased 126% to $5.9 million from $2.6 million at year-end 2024. Revenue contribution breakdown not explicitly detailed but revenue was $5,000 in Q2 2025.

Q: Jack Vander Aarde asks Tyler about his focus as CEO, management style, and future priorities.

A: Tyler states focus on execution/discipline, commercial acceleration, and product leadership for responsible AI engagement.

Q: Jack asks about the terminated acquisition of Cataneo and media space.

A: Walid says they're continuing to work with Cataneo, partnership is strong, and media is an important pillar with a need for nimble approach.

Q: Jack asks about the $5,000 revenue in Q2, if it's a pilot program.

A: Tyler says it's a pilot in hospitality with a client in Armenia and expects it to be recurring.

Q: Jack asks about pharmaceutical health care pilots.

A: Tyler says all pilots are moving forward, transitioning to scalable recurring relationships and expecting to share detailed results as programs formalize into commercial agreements.